Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal

Detalhes bibliográficos
Autor(a) principal: COSTA, C
Data de Publicação: 2016
Outros Autores: GONÇALO, M, GPEU – Grupo Português de Estudos de Urticária, Sokolova, A, et al.
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.10/1879
Resumo: Chronic spontaneous urticaria is a complex disorder, of unclear etiology, easily diagnosed although often difficult to treat. It has a significant impact on the patients' quality of life and results in high direct and indirect costs. The diagnosis of chronic spontaneous urticaria is mainly clinical and a limited number of tests is recommended for differential diagnosis and/or for the investigation/exclusion of possible causes. In addition to the complete blood count and C-reactive protein, and/or erythrocyte sedimentation rate, additional tests must be selected according to clinical criteria. The aim of therapy is the complete clinical control of chronic spontaneous urticaria. Evolution should be documented by weekly symptom scoring - Weekly Urticaria Activity Score (UAS7) -, as well as the assessment of quality of life. The therapeutic approach is based on second-generation H1 antihistamines (anti-H1) administered continuously in the approved doses (first line), and, in the absence of a clinical response, up to four times the daily-approved dose (second line). First generation H1 antihistamines are not recommended. Approximately 30% of patients are not controlled with second line therapy, and it is recommended to add a third line therapy. Of the two options, omalizumab and cyclosporine, only omalizumab is approved for chronic spontaneous urticaria and has a better safety profile, thus being preferably recommended. In Portugal there are no national-based recommendations applicable to clinical practice. The elaboration of these recommendations is justified by the need to standardize both the diagnosis and the treatment approach of patients with chronic spontaneous urticaria in Portugal, and for the referral of patients to specialized centers, in the most severe cases.
id RCAP_ec2baae38037d0b85d3ba3e65447fc0c
oai_identifier_str oai:repositorio.hff.min-saude.pt:10400.10/1879
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em PortugalDiagnostic and Therapeutic Approach of Chronic Spontaneous Urticaria: Recommendations in PortugalAntihistamínicosDoença crónicaUrticáriaPortugalChronic spontaneous urticaria is a complex disorder, of unclear etiology, easily diagnosed although often difficult to treat. It has a significant impact on the patients' quality of life and results in high direct and indirect costs. The diagnosis of chronic spontaneous urticaria is mainly clinical and a limited number of tests is recommended for differential diagnosis and/or for the investigation/exclusion of possible causes. In addition to the complete blood count and C-reactive protein, and/or erythrocyte sedimentation rate, additional tests must be selected according to clinical criteria. The aim of therapy is the complete clinical control of chronic spontaneous urticaria. Evolution should be documented by weekly symptom scoring - Weekly Urticaria Activity Score (UAS7) -, as well as the assessment of quality of life. The therapeutic approach is based on second-generation H1 antihistamines (anti-H1) administered continuously in the approved doses (first line), and, in the absence of a clinical response, up to four times the daily-approved dose (second line). First generation H1 antihistamines are not recommended. Approximately 30% of patients are not controlled with second line therapy, and it is recommended to add a third line therapy. Of the two options, omalizumab and cyclosporine, only omalizumab is approved for chronic spontaneous urticaria and has a better safety profile, thus being preferably recommended. In Portugal there are no national-based recommendations applicable to clinical practice. The elaboration of these recommendations is justified by the need to standardize both the diagnosis and the treatment approach of patients with chronic spontaneous urticaria in Portugal, and for the referral of patients to specialized centers, in the most severe cases.Ordem dos MédicosRepositório do Hospital Prof. Doutor Fernando FonsecaCOSTA, CGONÇALO, MGPEU – Grupo Português de Estudos de UrticáriaSokolova, A, et al.2017-06-22T14:32:25Z2016-01-01T00:00:00Z2016-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.10/1879porActa Med Port. 2016 Nov;29(11):763-7811646–075810.20344/amp.8294info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-20T15:52:36Zoai:repositorio.hff.min-saude.pt:10400.10/1879Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:52:54.822619Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
Diagnostic and Therapeutic Approach of Chronic Spontaneous Urticaria: Recommendations in Portugal
title Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
spellingShingle Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
COSTA, C
Antihistamínicos
Doença crónica
Urticária
Portugal
title_short Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
title_full Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
title_fullStr Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
title_full_unstemmed Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
title_sort Abordagem Diagnóstica e Terapêutica da Urticária Crónica Espontânea: Recomendações em Portugal
author COSTA, C
author_facet COSTA, C
GONÇALO, M
GPEU – Grupo Português de Estudos de Urticária
Sokolova, A, et al.
author_role author
author2 GONÇALO, M
GPEU – Grupo Português de Estudos de Urticária
Sokolova, A, et al.
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório do Hospital Prof. Doutor Fernando Fonseca
dc.contributor.author.fl_str_mv COSTA, C
GONÇALO, M
GPEU – Grupo Português de Estudos de Urticária
Sokolova, A, et al.
dc.subject.por.fl_str_mv Antihistamínicos
Doença crónica
Urticária
Portugal
topic Antihistamínicos
Doença crónica
Urticária
Portugal
description Chronic spontaneous urticaria is a complex disorder, of unclear etiology, easily diagnosed although often difficult to treat. It has a significant impact on the patients' quality of life and results in high direct and indirect costs. The diagnosis of chronic spontaneous urticaria is mainly clinical and a limited number of tests is recommended for differential diagnosis and/or for the investigation/exclusion of possible causes. In addition to the complete blood count and C-reactive protein, and/or erythrocyte sedimentation rate, additional tests must be selected according to clinical criteria. The aim of therapy is the complete clinical control of chronic spontaneous urticaria. Evolution should be documented by weekly symptom scoring - Weekly Urticaria Activity Score (UAS7) -, as well as the assessment of quality of life. The therapeutic approach is based on second-generation H1 antihistamines (anti-H1) administered continuously in the approved doses (first line), and, in the absence of a clinical response, up to four times the daily-approved dose (second line). First generation H1 antihistamines are not recommended. Approximately 30% of patients are not controlled with second line therapy, and it is recommended to add a third line therapy. Of the two options, omalizumab and cyclosporine, only omalizumab is approved for chronic spontaneous urticaria and has a better safety profile, thus being preferably recommended. In Portugal there are no national-based recommendations applicable to clinical practice. The elaboration of these recommendations is justified by the need to standardize both the diagnosis and the treatment approach of patients with chronic spontaneous urticaria in Portugal, and for the referral of patients to specialized centers, in the most severe cases.
publishDate 2016
dc.date.none.fl_str_mv 2016-01-01T00:00:00Z
2016-01-01T00:00:00Z
2017-06-22T14:32:25Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.10/1879
url http://hdl.handle.net/10400.10/1879
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Acta Med Port. 2016 Nov;29(11):763-781
1646–0758
10.20344/amp.8294
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130395712684032